CTA
ATRA icon

Carillon Tower Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Carillon Tower Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-48,810
Closed -$9.49M – 463
2020
Q1 		$9.49M Hold
48,810
– – 0.09% 278
2019
Q4 		$20.1M Hold
48,810
– – 0.13% 254
2019
Q3 		$17.2M Hold
48,810
– – 0.12% 267
2019
Q2 		$24.5M Hold
48,810
– – 0.17% 218
2019
Q1 		$48.5M Sell
48,810
-2,648
-5% -$2.46M 0.34% 100
2018
Q4 		$44.7M Hold
51,458
– – 0.38% 80
2018
Q3 		$53.2M Hold
51,458
– – 0.38% 83
2018
Q2 		$47.3M Hold
51,458
– – 0.37% 87
2018
Q1 		$47.5M Hold
51,458
– – 0.37% 82
2017
Q4 		$23.3M Buy
+51,458
New +$19M 0.25% 161

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Carillon Tower Advisers's ATRA Position: Q2 2020 in Review

Carillon Tower Advisers sold out of Atara Biotherapeutics (ATRA) in Q2 2020, closing a stake of 48,810 shares — an estimated $9.49M sold.

Carillon Tower Advisers first reported a position in ATRA in Q4 2017 and held it in 10 quarters. The position peaked at $53.2M in Q3 2018. 122 funds tracked by Wall St. Rank hold ATRA as of Q2 2020.

  • Carillon Tower Advisers reported no remaining Atara Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 48,810 Atara Biotherapeutics shares in Q2 2020, an estimated $9.49M.
  • Carillon Tower Advisers first reported a position in Atara Biotherapeutics in Q4 2017 and held it in 10 quarters.
  • Carillon Tower Advisers's Atara Biotherapeutics position peaked at $53.2M in Q3 2018.
  • 122 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2020.

Based on Carillon Tower Advisers's 13F filing for Q2 2020, filed 12 Aug 2020.